Produce less. Distribute it fairly. Create a greener world for all.

Syngenta says it will stop making paraquat – a pesticide linked to Parkinson’s disease

Syngenta, maker of a controversial pesticide linked to Parkinson’s disease, said on Tuesday that it will stop making its paraquat weed killer by the end of June.

Written by

Carey Gillam

in

Originally Published in

The New Lede

Syngenta, maker of a controversial pesticide linked to Parkinson’s disease, said on Tuesday that it will stop making its paraquat weed killer by the end of June.

The announcement comes as the company is facing several thousand lawsuits brought by people in the US who allege they developed Parkinson’s disease due to their exposure to Syngenta’s paraquat products.

The company did not mention the litigation in making the announcement, and did not respond to a request for comment.

The company’s announcement cites “significant competition” from generic producers of paraquat and a “less than 1 percent” contribution to the company’s global sales as reasons for exiting the paraquat business.

“This decision is about focusing our resources where they deliver the greatest value for our business and our customers,” Mike Hollands, President Syngenta UK and Head of Syngenta Global Production and Supply, said in a statement.

The company said it “affirms that paraquat is safe when used in line with registered label instructions,” and that paraquat remains “highly effective in controlling weeds.”

Paraquat has been used in the United States since 1964 as a tool to kill broadleaf weeds and grasses. Though banned in several countries, Syngenta’s paraquat-based Gramoxone herbicide brand has remained popular with US farmers for use in growing soybeans, cotton, and corn as well as in growing grapes, pistachios, peanuts and many other crops

Michael Okun, a neurologist and executive director of the Norman Fixel Institute for Neurological Diseases at the University of Florida who has called for a ban on paraquat, called the news a “public health milestone.”

“For decades we have warned that certain pesticides increase the risk of Parkinson’s and other serious diseases. This moment proves that advocacy, data, and courage can change the trajectory of disease,” Okun said.

Syngenta has always maintained that the evidence linking paraquat to Parkinson’s disease is “fragmentary” and “inconclusive.” But numerous scientific studies have found that paraquat damages cells in the brain in ways that can lead to Parkinson’s, and more than 8,000 lawsuits are pending in US courts over the Parkinson’s allegations. The company has settled several cases before they went to trial and has been negotiating to settle a bulk of the ongoing cases.

The New Lede, in conjunction with The Guardian, obtained and revealed many of Syngenta’s internal corporate files, which show that not only was Syngenta aware of research linking paraquat to Parkinson’s decades ago, but it also sought to secretly influence scientific information and public opinion regarding those links. The New Lede maintains a library of some of the documents.

Lawmakers in multiple states have introduced legislation to ban paraquat and several federal lawmakers have also called for bans on the chemical.

“If this is true then fewer people are going to develop Parkinson’s disease in the future,” said Ray Dorsey, a neurologist and director of the Atria Research Institute’s Center for the Brain & the Environment, a nonprofit research initiative investigating the environmental causes of brain diseases. “It also means that the voices of the Parkinson’s community, the voices of those who’ve been highlighting the toxic effects of this weed killer … are being heard and they’re having impact.”

Nathan Donley, environmental health science director with the Center for Biological Diversity, noted that while Syngenta has long been known as a key supplier of paraquat in the US, other companies supply generic versions of paraquat.

“It’s great news that Syngenta is exiting the paraquat business, but it’s also a reminder that smaller companies will readily fill the void as long as this poison remains approved in our borders,” Donley said.

Carey Gillam is the editor-in-chief of The New Lede and a veteran investigative journalist with more than 30 years of experience covering US news, including 17 years as a senior correspondent with Reuters international news service (1998-2015). She is the author of “Whitewash – The Story of a Weed Killer, Cancer and the Corruption of Science,” an expose of Monsanto’s corporate corruption of agriculture. The book won the coveted Rachel Carson Book Award from the Society of Environmental Journalists in 2018. Her second book, a narrative legal thriller titled The Monsanto Papers, was released March 2, 2021. She also has contributed chapters for a text book about environmental journalism and a book about pesticide use in Africa. Gillam testified as an invited expert before the European Parliament in 2017 about her research, and was a featured speaker at the World Forum for Democracy in Strasbourg, France in 2019. She also has been a keynote and/or panel speaker at events and universities throughout North America, Australia, The Netherlands, Brussels, and France. Gillam writes regularly for The Guardian. Her work has additionally been published in The New York Times, Huffington Post, Time, and other outlets. In 2022, Gillam helped launch The New Lede as a journalism initiative of the Environmental Working Group. Gillam is a member of the Society of Environmental Journalists.